<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03366337</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-1702</org_study_id>
    <nct_id>NCT03366337</nct_id>
  </id_info>
  <brief_title>A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX</brief_title>
  <acronym>PHOENIX</acronym>
  <official_title>A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy
      of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases
      (CKD): CKD associated with type 1 diabetes (T1D), IgA nephropathy (IgAN), focal segmental
      glomerulosclerosis (FSGS), and autosomal dominant polycystic kidney disease (ADPKD). Patients
      will be enrolled in disease specific cohorts within the trial, and effectiveness of
      bardoxolone methyl in treating CKD will be assessed separately by cohort for each rare CKD.

      All patients in the study will follow the same visit and assessment schedule. Following
      randomization on Day 1, patients will be scheduled to be assessed during treatment at Weeks
      1, 2, 4, 6, 8, and 12, and by telephone contact on Days 3, 10, 21, 31, 38, and 45. Patients
      will also be scheduled to be assessed at an in-person follow-up visit at Week 16, four weeks
      after the end of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2017</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in eGFR from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>To assess the increase in eGFR from baseline to week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety will be assessed by monitoring laboratory results, vital sign measurements, electrocardiogram results, adverse events, and serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>IgA Nephropathy</condition>
  <condition>CKD Associated With Type 1 Diabetes</condition>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <condition>Autosomal Dominant Polycystic Kidney</condition>
  <arm_group>
    <arm_group_label>Patients with baseline ACR &gt; 300 mg/g but ≤ 2,500 mg/g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive bardoxolone methyl throughout the study. Patients with baseline ACR &gt; 300 mg/g will be titrated to a maximum dose of 30 mg of bardoxolone methyl. They will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, 20 mg at week 4, and then to 30 mg at Week 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with baseline ACR ≤ 300 mg/g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive bardoxolone methyl throughout the study. Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg of bardoxolone methyl. They will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2 and 20 mg at week 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl capsules</intervention_name>
    <description>Bardoxolone 5 mg capsules</description>
    <arm_group_label>Patients with baseline ACR &gt; 300 mg/g but ≤ 2,500 mg/g</arm_group_label>
    <arm_group_label>Patients with baseline ACR ≤ 300 mg/g</arm_group_label>
    <other_name>RTA 402</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients 18 ≤ age ≤ 65 upon study consent;

          -  Screening eGFR (average of Screen A and Screen B eGFR values) ≥ 30 and ≤ 90
             mL/min/1.73 m2. The two eGFR values collected at Screen A and Screen B visits used to
             determine eligibility must have a percent difference ≤ 25%;

          -  Albumin to creatinine ratio (ACR) ≤ 2500 mg/g at Screen B visit;

          -  If receiving an angiotensin-converting enzyme (ACE) inhibitor and/or an angiotensin II
             receptor blocker (ARB), patients should be prescribed the maximally tolerated labeled
             daily dose (MTLDD) for at least 6 weeks prior to the Screen A visit;

          -  For patients enrolling in T1D Cohort: Diagnosis of type 1 diabetes confirmed by
             fasting C-peptide level. Diagnosis must have been made ≤ 35 years of age; and
             prescribed stable dose of insulin to maintain adequate glucose control for at least 6
             months prior to the Screen A visit;

          -  For patients enrolling in IgAN Cohort: Biopsy-confirmed IgA nephropathy;

          -  For patients enrolling in FSGS Cohort: Biopsy-confirmed FSGS that is not due to known
             secondary causes including morbid obesity, decreased renal mass, viral infections,
             drug-induced nephrotoxicity, or prior history of vasculitis;

          -  For patients enrolling in ADPKD Cohort: Genetic confirmation of PKD1 mutation;

          -  Adequate bone marrow reserve and organ function at the Screen A visit as follows:
             Hematologic: Absolute neutrophil count &gt; 1.5 x 109/L, platelets &gt; 100 x 109/L,
             hemoglobin (Hgb) ≥ 9 g/dL; and Hepatic: Total bilirubin (TBL) ≤ 1.5 times the upper
             limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase
             (AST) ≤ 1.5 times ULN.

        Exclusion Criteria:

          -  Kidney or any other solid organ transplant recipient or a planned transplant during
             the study;

          -  B-type natriuretic peptide (BNP) level &gt; 200 pg/mL at Screen A visit;

          -  Acute dialysis or acute kidney injury within 12 weeks prior to Screen A visit or
             during Screening;

          -  Serum albumin &lt; 3 g/dL at Screen A visit;

          -  Systemic immunosuppression for more than 2 weeks, cumulatively, within the 12 weeks
             prior to randomization or anticipated need for immunosuppression during the study;

          -  For patients enrolling in IgAN Cohort: Systemic manifestations of Henoch-Schonlein
             purpura within 1 year prior to Screen A visit; or have used belimumab, eculizumab, or
             rituximab within 6 months prior to Screen A visit;

          -  For patients enrolling in ADPKD Cohort: Receiving tolvaptan;

          -  Cerebrovascular event (stroke, transient ischemic attack) or aneurysm within 6 months
             prior to Screen A visit or during Screening;

          -  History of clinically significant left-sided heart disease and/or clinically
             significant cardiac disease;

          -  Uncontrolled systemic hypertension;

          -  Systolic BP &lt; 90 mm Hg at Screen A visit after a period of rest;

          -  History of malignancy within 2 years prior to Screen A visit, with the exception of
             localized skin or cervical carcinomas;

          -  Uncontrolled diabetes (HbA1c &gt; 10.0%) at Screen A visit;

          -  Untreated or uncontrolled active bacterial, fungal, or viral infection;

          -  Participation in other interventional clinical studies within 30 days prior to Day 1;

          -  Unwilling to practice acceptable methods of birth control (both males who have
             partners of child-bearing potential and females of childbearing potential) during
             Screening, while taking study drug, and for at least 30 days after the last dose of
             study drug is ingested;

          -  Women who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Angela Germany</last_name>
    <phone>469-442-4900</phone>
    <email>phoenix@reatapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dana Rizk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phoenician Centers for Research &amp; Innovation (PCRI)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kenneth Boren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Denver Nephrology</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Geoffrey Block, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gulfcoast Endocrine and Diabetes Center</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Denker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Florida Research Institute</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33313</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Edouard R Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Nephrology Associates</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rohit Pankhaniya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kidney Care Augusta</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Syed N Babar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boise Kidney &amp; Hypertension, PLLC</name>
      <address>
        <city>Caldwell</city>
        <state>Idaho</state>
        <zip>83605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arnold L Silva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boise Kidney &amp; Hypertension, PLLC</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arnold Silva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research By Design</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Crawford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cassandra Kimber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Four Rivers Clinical Research, Inc</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cynthia Bowman-Stroud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Louisiana Nephrology</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marwan Kaskas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center - Division of Nephrology Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lesley Inker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consultants, LLC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ahmed Awad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>George Jarad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anjali Acharya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Physician's East Endocrine Research</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Warren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Remington-Davis Clinical Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kevin Schroeder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research Center, LLC</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nelson Kopyt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Warren Alpert School of Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Reginald Gohh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claude Galphin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Management, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Judith Betts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renal Disease Research Intitute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tapan Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renal Associates, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pablo Pergola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Barbara Rizzardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mendez Center for Clinical Research LLC</name>
      <address>
        <city>Fairfax Station</city>
        <state>Virginia</state>
        <zip>22039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ramon Mendez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Larry Stonesifer, M.D.</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Larry Stonesifer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.phoenixclinicaltrial.com/</url>
    <description>Link to the PHOENIX trial website, which contains information about the trial and participating centers</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>December 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IgA Nephropathy</keyword>
  <keyword>CKD associated with type 1 diabetes</keyword>
  <keyword>Focal segmental glomerulosclerosis</keyword>
  <keyword>Autosomal dominant polycystic kidney disease</keyword>
  <keyword>IgAN</keyword>
  <keyword>FSGS</keyword>
  <keyword>ADPKD</keyword>
  <keyword>Bardoxolone methyl</keyword>
  <keyword>CDDO-ME</keyword>
  <keyword>RTA 402</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

